NPPA issued a notification regarding the fixation of the retail price of Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg + Glimepiride IP 1 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer)

Mar 07, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific ComplianceThe National Pharmaceutical Pricing Authority (NPPA) on March 06, 2026, issued a notification regarding the fixation of the retail price of Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg + Glimepiride IP 1 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer).

The following has been stated: -

•For each film-coated tablet containing Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg + Glimepiride IP 1 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer), the retail price is 10.39 (Rs).

[Notification No.:19(5056)/2026/DP/NPPA/Div.III/13314/2026]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT